Question 13

The Qsymia REMS program is intended to help prevent embryo-fetal exposure.

The Qsymia REMS program is specifically designed to mitigate the risks associated with the use of the medication during pregnancy, particularly focusing on preventing embryo-fetal exposure.

A) Embryo-fetal exposure

This option is correct as the Qsymia REMS program is implemented to prevent embryo-fetal exposure, which poses significant risks to fetal development when the medication is used by pregnant women.

B) Respiratory depression

While respiratory depression can be a concern with various medications, it is not the primary focus of the Qsymia REMS program. This program does not specifically address this issue as a primary intent.

C) Fatal hemorrhage

Fatal hemorrhage is not a primary concern associated with Qsymia use, and thus it is not related to the objectives of the REMS program. The focus of the program lies elsewhere.

D) Vision loss

Vision loss is not directly related to the REMS program for Qsymia. The program does not aim to prevent this condition, as it is unrelated to the specific risks addressed by the medication's guidelines.

Conclusion

The focus of the Qsymia REMS program is clearly on preventing embryo-fetal exposure, which is crucial for protecting fetal health during pregnancy. Other options such as respiratory depression, fatal hemorrhage, and vision loss do not align with the primary objectives of the program, making them incorrect. Thus, option A is the definitive correct choice.